Aion Therapeutic Inc.

    Aion Therapeutic Inc.

    CCSE:AION
    0.01
    CAD
    0.00
    (0.00%)

    Share Statistics

    As of January 31, 2025, Aion Therapeutic Inc. has 497.15M shares outstanding.

    Shares Outstanding497.15M

    Valuation Ratios

    These figures are as of January 31, 2025. The price-to-sales ratio is 3.24, and the price-to-book ratio stands at -0.68.

    PS Ratio3.24
    PB Ratio-0.68
    P/TBV Ratio-1.02
    P/FCF Ratio-3.09
    P/OCF Ratio-3.09

    Enterprise Valuation

    These figures are as of January 31, 2025. The EV/Sales ratio of 5.14 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

    EV / Sales5.14

    Financial Position

    As of January 31, 2025, Aion Therapeutic Inc. maintains a current ratio of 0.19, meaning it holds 0.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -60.12, indicating conservative leverage, while an interest coverage ratio of -4.41 demonstrates limited ability to service its debt obligations.

    Current Ratio0.19
    Quick Ratio0.03
    Debt / Equity-60.12
    Debt / EBITDA-1.92
    Interest Coverage-4.41

    Financial Efficiency

    These figures cover the twelve months ended January 31, 2025. Return on assets (ROA) is negative at -187.35, reflecting losses generated across the asset base. Inventory turnover of 2.28 indicates how many times Aion Therapeutic Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

    Return on Assets (ROA)-187.35
    Inventory Turnover2.28

    Stock Price Statistics

    CAD

    As of the close on October 1, 2025, Aion Therapeutic Inc.'s stock has declined approximately 66.67% over the past 52 weeks. The 50-day moving average sits at 0.01, while the 200-day moving average is 0.01.

    52-Week Price Change-66.67%
    50-Day Moving Average0.01
    200-Day Moving Average0.01

    Margins

    Over the twelve months ended January 31, 2025, Aion Therapeutic Inc. posted a gross margin of 37.50, reflecting its pricing power and cost economics. The operating margin of -107.43 and net profit margin of -451.18 provide insight into operational efficiency.

    Gross Margin37.50
    Operating Margin-107.43
    Pretax Margin-451.18
    Profit Margin-451.18
    EBITDA Margin-99.13

    Dividends & Yields

    These figures cover the twelve months ended January 31, 2025. Free cash flow yield is negative at -32.35: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -29.55, meaning Aion Therapeutic Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

    Shareholder Yield-29.55
    FCF Yield-32.35

    Scores

    As of January 31, 2025, Aion Therapeutic Inc. has an Altman Z-Score of -39.40, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

    Altman Z-Score-39.40